

Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing



Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic

<ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing</i></b>

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
Turn Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TTRX">TTRX</a>), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq&#39;s invitation to mark its progress to date.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;We&#39;re honored that Nasdaq invited us back to share our story,&#34; said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. &#34;Over the past year we&#39;ve made meaningful progress, but what I&#39;m most proud of is that we got here by refusing to believe there was only one way to build a biotech company. Turn Therapeutics was founded on the principle that patients deserve targeted, localized therapies rather than systemic treatment whenever possible. We challenged conventional thinking in our science, in how we built the company, and in how we came to the public markets. I hope our story reminds other entrepreneurs that &#39;the usual way&#39; isn&#39;t the only way.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Overview of Event Details</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Nasdaq Bell Ringing Ceremony</b>

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
Event Date: Monday, August 10, 2026

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Time: The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Location: Nasdaq MarketSite, Times Square, New York

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Event Livestream Link: <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nasdaq.com%2Fmarketsite%2Fbell-ringing-ceremony&amp;esheet=54578255&amp;newsitemid=20260728763249&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nasdaq.com%2Fmarketsite%2Fbell-ringing-ceremony&amp;index=1&amp;md5=37c094d13420d32c0ceda1972ee4e0e8" shape="rect">https://www.nasdaq.com/marketsite/bell-ringing-ceremony</a>

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Turn Therapeutics</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics&#39; lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.turntherapeutics.com&amp;esheet=54578255&amp;newsitemid=20260728763249&amp;lan=en-US&amp;anchor=www.turntherapeutics.com&amp;index=2&amp;md5=82e6ca3aafd288ec280fd1afbe095804" shape="rect">www.turntherapeutics.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn Therapeutics undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260728763249r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260728763249/en/" rel="nofollow">https://www.businesswire.com/news/home/20260728763249/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Turn Therapeutics Investor &amp; Media Contact
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Sasha Damouni
<br xmlns="http://www.w3.org/1999/xhtml"></br>The Damouni Group
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Sasha@damounigroup.com" shape="rect">Sasha@damounigroup.com</a>

</p>

TTRX

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics to Ring Nasdaq Closing Bell, Highlighting Progress Since Direct Listing

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing



Turn Therapeutics Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, non-systemic</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Turn Therapeutics will ring the Nasdaq Closing Bell on August 10, 2026, signaling market visibility after its October 2025 direct listing. The event spotlights the companys push toward localized, non-systemic therapies like GX-03 for atopic dermatitis. While this boosts branding and investor interest, meaningful upside hinges on GX-03 clinical progress and funding needs.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Turn Therapeutics to ring Nasdaq Closing Bell on Aug 10, 2026.</li><li>Event underscores progress since Oct 2025 direct listing.</li><li>GX-03 is Turn&#039;s lead topical candidate for atopic dermatitis.</li><li>Company emphasizes targeted, localized therapies over systemic treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Turn Therapeutics Inc. (TTRX)</strong>: Primary subject; bell ceremony could boost visibility and investor interest.</li><li><strong>Nasdaq, Inc. (NDAQ)</strong>: Hosting the bell ceremony; potential indirect uplift to Turn&#039;s branding and liquidity.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. This centers on a public recognition event tied to a biotech issuer, highlighting visibility and branding rather than new clinical data or financing announcements.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Nasdaq Closing Bell event dated August 10, 2026 could attract media attention.</li><li>Increased investor attention may provide a short-term price/volume lift for TTRX.</li><li>No new clinical data announced; fundamental value remains tied to GX-03 progress and financing.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Ticker: TTRX (Turn Therapeutics Inc.) on Nasdaq.</li><li>Event Date: August 10, 2026; Closing Bell broadcast at 3:45 p.m. ET.</li><li>Location: Nasdaq MarketSite, Times Square, New York.</li><li>Direct listing occurred in October 2025.</li><li>GX-03 is Turn&#039;s lead topical candidate for atopic dermatitis; designed to be non-systemic.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term bullish on visibility; longer-term depends on GX-03 data and financing within 6–12 months.</p>
  </section>
</section>


<ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><i xmlns="http://www.w3.org/1999/xhtml">Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing</i></b>

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
Turn Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TTRX">TTRX</a>), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq&#39;s invitation to mark its progress to date.

</p><p xmlns="http://www.w3.org/1999/xhtml">
&#34;We&#39;re honored that Nasdaq invited us back to share our story,&#34; said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. &#34;Over the past year we&#39;ve made meaningful progress, but what I&#39;m most proud of is that we got here by refusing to believe there was only one way to build a biotech company. Turn Therapeutics was founded on the principle that patients deserve targeted, localized therapies rather than systemic treatment whenever possible. We challenged conventional thinking in our science, in how we built the company, and in how we came to the public markets. I hope our story reminds other entrepreneurs that &#39;the usual way&#39; isn&#39;t the only way.&#34;

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Overview of Event Details</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Nasdaq Bell Ringing Ceremony</b>

</p><ul xmlns="http://www.w3.org/1999/xhtml" class="bwlistdisc">
<li xmlns="http://www.w3.org/1999/xhtml">
Event Date: Monday, August 10, 2026

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Time: The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Location: Nasdaq MarketSite, Times Square, New York

</li>
<li xmlns="http://www.w3.org/1999/xhtml">
Event Livestream Link: <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nasdaq.com%2Fmarketsite%2Fbell-ringing-ceremony&amp;esheet=54578255&amp;newsitemid=20260728763249&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nasdaq.com%2Fmarketsite%2Fbell-ringing-ceremony&amp;index=1&amp;md5=37c094d13420d32c0ceda1972ee4e0e8" shape="rect">https://www.nasdaq.com/marketsite/bell-ringing-ceremony</a>

</li>
</ul><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Turn Therapeutics</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics&#39; lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression. For more information, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.turntherapeutics.com&amp;esheet=54578255&amp;newsitemid=20260728763249&amp;lan=en-US&amp;anchor=www.turntherapeutics.com&amp;index=2&amp;md5=82e6ca3aafd288ec280fd1afbe095804" shape="rect">www.turntherapeutics.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn Therapeutics undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260728763249r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260728763249/en/" rel="nofollow">https://www.businesswire.com/news/home/20260728763249/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Turn Therapeutics Investor &amp; Media Contact
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Sasha Damouni
<br xmlns="http://www.w3.org/1999/xhtml"></br>The Damouni Group
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Sasha@damounigroup.com" shape="rect">Sasha@damounigroup.com</a>

</p>

Turn Therapeutics will ring the Nasdaq Closing Bell on August 10, 2026, signaling market visibility after its October 2025 direct listing. The event spotlights the companys push toward localized, non-systemic therapies like GX-03 for atopic dermatitis. While this boosts branding and investor interest, meaningful upside hinges on GX-03 clinical progress and funding needs.

News insight

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

AI summary

Sentiment rationale

Key facts

Corporate Developments